论文部分内容阅读
目的：探究替米沙坦联合氨氯地平治疗慢性肾脏病（CKD）合并早期高血压患者的临床疗效。方法研究对象为医院收治的79例CKD合并早期高血压患者，按照随机数字法分为两组，对照组35例仅口服氨氯地平治疗，观察组44例则联合应用替米沙坦与氨氯地平，分析对比两组采用不同治疗方法治疗后效果。结果两组患者降压疗效、血压下降情况对比有明显差异，P＜0.05，两组治疗后肝功能指标、肌酐水平无差异，P＞0.05，微量白蛋白水平对比差异显著P＜0.05，两组不良反应轻微对比无差异P＞0.05。结论 CKD合并早期高血压应用氨氯地平与替米沙坦治疗效果确切，且安全可靠。“,”Objective To explore the telmisartan with amlodipine therapy in chronic kidney disease (CKD) to merge the clinical curative effect of early patients with high blood pressure. Methods The object of study for the hospital treated 79 cases of chronic kidney disease (CKD) merger early patients with high blood pressure, according to the method of random Numbers are divided into two groups, control group 35 cases only oral amlodipine therapy, observation group of 44 cases of combined use of telmisartan and amlodipine, analyzed two groups with different treatment effect after treatment. Results Two groups of patients with hypertension treatment, blood pressure reduction compared with significant difference, P 0.05, trace albumin levels compared to significant difference P 0.05). Conclusion Chronic kidney disease (CKD) merger early hypertension application of telmisartan and amlodipine therapy effect is exact, safe and reliable.